Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 73 (2) , 142-150
Abstract
No abstract availableKeywords
Funding Information
- Korea Centers for Disease Control and Prevention (2016-ER6304-01)
This publication has 36 references indexed in Scilit:
- Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesNew England Journal of Medicine, 2013
- Early versus delayed percutaneous coronary intervention for patients with non‐ST segment elevation acute coronary syndrome: A meta‐analysis of randomized controlled clinical trialsCatheterization and Cardiovascular Interventions, 2012
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromesEuropean Heart Journal, 2010
- A Risk Score to Predict Bleeding in Patients With Acute Coronary SyndromesJACC, 2010
- Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk ScoresPLOS ONE, 2009
- Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromesHeart, 2008
- Universal Definition of Myocardial InfarctionCirculation, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988